ADS Capstone Chronicles Revised

‭33‬

‭U.S. Department of Health and Human‬ ‭Services. (2023, October 6). Office‬ ‭of the Assistant Secretary for‬ ‭Planning and Evaluation: Changes in‬ ‭the list prices of prescription drugs,‬ ‭2017–2023.‬ ‭https://aspe.hhs.gov/reports/changes-‬ ‭list-prices-prescription-drugs‬ ‭U.S. Department of Health and Human‬ ‭Services. (2024, May 31).‬ ‭Inflation‬ ‭reduction act of 2022‬ ‭.‬ ‭https://www.hhs.gov/inflation-reduct‬ ‭ion-act/index.ht‬ ‭U.S. Department of Veterans Affairs. (n.d.).‬ ‭National drug file - Reference‬ ‭terminology (NDF-RT).‬ ‭https://evs.nci.nih.gov/ftp1/NDF-RT/‬ ‭U.S. Food and Drug Administration.‬ ‭(n.d.-a).‬ ‭About the openFDA API‬ ‭.‬ ‭https://open.fda.gov/apis/‬ ‭U.S. Food and Drug Administration.‬ ‭(n.d.-b).‬ ‭Drug adverse event‬ ‭overview‬ ‭.‬ ‭https://open.fda.gov/apis/drug/event/‬ ‭U.S. Food and Drug Administration.‬ ‭(n.d.-c).‬ ‭Drug labeling overview‬ ‭.‬ ‭https://open.fda.gov/apis/drug/label/‬ ‭U.S. Food and Drug Administration.‬ ‭(n.d.-d).‬ ‭Historical documents‬ ‭overview‬ ‭.‬ ‭https://open.fda.gov/apis/other/histor‬ ‭icaldocument/‬ ‭U.S. Food and Drug Administration‬‭. (2018a,‬ ‭February 5).‬ ‭Understanding‬ ‭unapproved use of approved drugs‬ ‭“Off label.”‬ ‭https://www.fda.gov/patients/learn-a‬ ‭bout-expanded-access-and-other-trea‬ ‭tment-options/understanding-unappr‬ ‭oved-use-approved-drugs-label‬

‭U.S. Food and Drug Administration‬‭. (2018b,‬ ‭June 4).‬ ‭Questions and answers on‬ ‭FDA's Adverse Event Reporting‬ ‭System (FAERS).‬ ‭https://www.fda.gov/drugs/surveillan‬ ‭ce/questions-and-answers-fdas-adver‬ ‭se-event-reporting-system-faers‬ ‭U.S. Food and Drug Administration. (2023a,‬ ‭October 5).‬ ‭Generic competition and‬ ‭drug prices‬ ‭.‬ ‭https://www.fda.gov/about-fda/center‬ ‭-drug-evaluation-and-research-cder/g‬ ‭eneric-competition-and-drug-prices‬ ‭U.S. Food and Drug Administration. (2023b,‬ ‭https://www.fda.gov/drugs/questions‬ ‭-and-answers-fdas-adverse-event-rep‬ ‭orting-system-faers/fda-adverse-even‬ ‭t-reporting-system-faers-public-dash‬ ‭board‬ ‭Wang, C. S., Lin, P. J., Cheng, C. L., Tai, S.‬ ‭H., Kao Yang, Y. H., & Chiang, J. H.‬ ‭(2019). Detecting potential adverse‬ ‭drug reactions using a deep neural‬ ‭network model.‬ ‭Journal of Medical‬ ‭Internet Research‬ ‭,‬ ‭21‬ ‭(2), e11016.‬ ‭https://doi.org/‬‭10.2196/11016‬ ‭Weininger, D. (1988). SMILES, a chemical‬ ‭language and information system. 1.‬ ‭Introduction to methodology and‬ ‭encoding rules.‬ ‭Journal of Chemical‬ ‭Information and Computer Sciences‬ ‭,‬ ‭28‬ ‭(1), 31–36.‬ ‭https://doi.org/‬‭10.1021/ci00057a005‬ ‭Wightman, R. S., Perrone, J., Scagos, R.,‬ ‭Hallowell, B. D., Krieger, M., Li, Y.,‬ ‭McGregor, A. J., Nelson, L. S., &‬ ‭Marshall, B. D. L. (2021).‬ ‭Toxicological and pharmacologic sex‬ ‭differences in unintentional or‬ ‭December 7).‬ ‭FDA adverse event‬ ‭reporting system (FAERS) public‬ ‭dashboard‬ ‭.‬

183